Based on the favor-
able safety profile observed in that first pediatric trial, a
randomized, observer-blind, controlled trial was conducted
in 51 infants, 12
–
15 months of age, who also had no detect-
able neutralizing antibodies to any DENV serotype or to
JEV. Infants received two doses of F17/Pre vaccine 6 months
apart (either a 1/10 dose, or full dose) or control vaccines.